iPremom
A Valencia healthtech combining cell-free RNA in maternal blood with predictive models through its MaiRa platform.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Conveo, HyImpulse, iPremom — $50M for consumer AI, €50M+ for rockets and €15M for prenatal diagnostics — Daily News September 2, 2026
Listen to the episodeAbout iPremom
iPremom develops MaiRa, a platform that analyses molecular signals in maternal blood during the first trimester and applies predictive modelling to assess the risk of pregnancy complications. The new capital will fund clinical validation, regulatory approvals and commercialisation.
The Story
Founded in Valencia in 2019 around the research of Carlos Simón and Tamara Garrido.
How iPremom works
Business Model
Molecular diagnostics for laboratories, healthcare professionals and patients.
Revenue Model
Sale and processing of diagnostic tests through its laboratory and future healthcare partners; prices and terms have not been disclosed.
Products & Services
Key Products
- MaiRa
Core Use Cases
- Early preeclampsia risk assessment
- Molecular analysis of maternal blood
- Predictive modelling of pregnancy complications
- Support for clinical monitoring
Market & Clients
Key Customers
Laboratories, clinics, healthcare professionals and pregnant individuals.
Geographic Presence
How iPremom competes
Competitive Advantages
- cfRNA analysis from the first trimester
- Research developed on clinical samples
- Combination of biomarkers and predictive models
How iPremom grows
Growth Strategy
Complete validation studies, obtain approvals in the EU and the US, and expand commercial access.
Distribution Model
Proprietary laboratory in Spain and future partnerships with healthcare providers.
Moat (Defensibility)
Clinical data, biomarkers, predictive algorithms, diagnostic know-how and regulatory approvals.
Regulatory Context
MaiRa is subject to diagnostic-device regulation, clinical validation requirements and health-data protection rules.
Key Risks
- Clinical validation still to be completed
- Timing and outcome of regulatory approvals
- Differing performance across populations
- Liability related to false positives and negatives
- Protection of sensitive health data
Strategic Insights
- Combining biomarkers with predictive models requires clinical evidence beyond algorithmic performance.
- Regulatory approval and healthcare distribution will matter as much as the technology.
Funding & Investors
Funding Rounds
- 2026 - Seed: €15M
Lead: Amadeus Capital Partners
Key Investors
Founding Team
Founders
Key Executives
- Guillermo Ferrando Huertas - CEO
Key Metrics
Lessons from iPremom
- In clinical markets, a large dataset does not replace prospective validation.
- Diagnostic claims must remain proportionate to the approvals obtained.
Similar Startups
Idoven 1903 SL
AI-powered cardiology platform that revolutionises ECG interpretation, enabling early detection of heart conditions and improving diagnostic precision.
Read AnalysisPragmatech
Pragmatech has developed an AI platform for dermatological image analysis that assists physicians in recognising suspicious skin lesions for early detection of melanoma and other skin cancers.
Read AnalysisSources
- iPremom raises €15m to transform pregnancy care with molecular diagnostics — Amadeus Capital Partners
- iPremom raises €15 million to advance early detection — EU-Startups
- MaiRa pregnancy risk assessment — iPremom